News | October 27, 2021
Torrent Pharma consolidated PAT at Rs 316 cr. in Q2FY22
Torrent Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
Torrent Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
FDI increased 98% year on year in 2020 and pharma exports grew by 18% in the last financial year
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
Drugs and pharmaceuticals were among the top eight export items in H1FY22, according to a Care Ratings report.
It has planned an investment of over Rs 80 crore in the next five years
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
The injection is used to reverse the effects of the muscle relaxants given to patients during surgery
The company plans to expand its portfolio in regulated markets aggressively
The company's sustainability programme was evaluated on its policies, actions put in place to support objectives and targets, as well as results that were generated from the programme
Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
Subscribe To Our Newsletter & Stay Updated
